A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

November 23, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

July 30, 2025

Conditions
HER2 Expressing or Mutated Advanced Malignant Solid Tumors
Interventions
DRUG

GQ1005

an antibody drug conjugate

Trial Locations (20)

100039

RECRUITING

Chinese PLA general hospital, Beijing

110136

RECRUITING

Shengjing hospital of China medical universty, Shenyang

150007

RECRUITING

The First Affiliated Hospital of Haerbin Medical University, Haerbin

200032

RECRUITING

Fudan university Shanghai Cancer Center, Shanghai

210008

RECRUITING

Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing

250117

RECRUITING

Shandong Cancer Hospital, Jinan

264099

RECRUITING

Yantai Yuhuangding Hospital, Yantai

276002

RECRUITING

Linyi Cancer Hospital, Linyi

300181

RECRUITING

Tianjin medical university cancer institute & hospital, Tianjin

310020

RECRUITING

Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine, Hangzhou

350014

RECRUITING

Fujian Cancer Hospital, Fuzhou

RECRUITING

Fujian Cancer Hospital, Fuzhou

400042

RECRUITING

The First Affiliated Hospital of Chongqing Medical University, Chongqing

450003

RECRUITING

Henan Cancer Hospital, Zhengzhou

450052

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

453199

RECRUITING

The First Affiliated Hospital of Xinxiang Medical University, Xinxiang

610042

RECRUITING

Sichuan Cancer Hospital, Chengdu

629099

RECRUITING

Suining Central Hospital, Suining

710061

RECRUITING

The First Affiliated Hospital of Xi'an University, Xi'an

Unknown

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

GeneQuantum Healthcare (Suzhou) Co., Ltd.

INDUSTRY